Page 300 - Haematologica April 2020

F. Baron et al.
adjusting for potential confounding factors by multivariate analyses there was no significant impact of the graft type on relapse (HR=1.0, 95% CI: 0.8-1.2, P=0.6). In contrast, a more recent year of transplantation (HR=1.1, 95% C1: 1.0-1.2, P=0.02) was associated with a higher risk of
relapse. There was no interaction between the association of graft type and the risk of relapse and year of transplan- tation (interaction test P=0.38). Unadjusted comparison of relapse incidence between the two groups per 6-year peri- ods is shown in the Online Supplementary Table S2. We fur-
A
OS in MUD
Multivariate Cox model P=0.04 Univariate log-rank P=0.36
RI in MUD
Multivariate Cox model P=0.93 Univariate Gray P=0.41
cGvHD in MUD
Multivariate Cox model P<0.001 Univariate Gray P<0.001
B LFS in MUD
Multivariate Cox model P=0.17 Univariate log-rank P=0.71
D NRM in MUD
Multivariate Cox model P=0.07 Univariate Gray P=0.16
F GRFS in MUD
Multivariate Cox model P=0.001
Univariate log-rank P=0.002
C
E
Figure 2. Comparison of outcomes in bone marrow (BM) patients without anti-thymocyte globulin (ATG)and in those given peripheral blood (PB) stem cells with ATG (the dotted line shows the PBSC with ATG curve adjusted for relevant covariates) in the cohort of patients receiving grafts from 10/10 HLA-matched unrelated donors (MUD). (A) Overall survival (OS), P=0.36. (B) Leukemia-free survival (LFS), P=0.71. (C) Incidence of relapse (RI), P=0.41.(D) Non-relapse mortality (NRM), P=0.16. (E) Chronic graft-versus-host disease (cGvHD), P<0.001. (F) GvHD-free and relapse-free survival (GRFS), P=0.002.
1142
haematologica | 2020; 105(4)